The similar and favorable outcomes for mice with HCT116 and HT29 derived flank tumors marked by impaired Acss2/HIF-2 signaling suggest that targeting this pathway may have broad efficacy in colon cancer. This evidence concerns the gene ACSS2 and colonic neoplasm.